Atopic dermatitis: novel H4 receptor antagonist shows benefit in RCT

  • Werfel T & al.
  • J Allergy Clin Immunol
  • 8 Nov 2018

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Results from a randomized controlled trial (RCT) suggest that the histamine H4 receptor antagonist ZPL-3893787 is associated with clinical improvement in patients with atopic dermatitis (AD).

Why this matters

  • ZPL-3893787 may represent a promising new treatment option for AD, which is needed for patients with moderate to severe disease not adequately controlled with topical agents.

Key results

  • At 8 weeks, ZPL-3893787 was associated with a greater reduction in the Eczema Area and Severity Index (50% vs 27%, P=.010) and in Scoring Atopic Dermatitis (41% vs 26%, P=.004).
  • ZPL-3893787 and placebo were associated with 18.5% and 9.1% of patients, respectively, considered to be clear or almost clear by Investigator’s Global Assessment (P=.088).
  • ZPL-3893787 and placebo were associated with similar reductions in pruritus (P=.249).
  • ZPL-3893787 and placebo were associated with similar incidence of treatment-emergent adverse events (66% vs 64%).

Study design

  • 98 patients with moderate to severe AD from 17 centers in 4 countries were randomly assigned 2:1 to receive ZPL-3893787 (N=65) or placebo (N=33) for 8 weeks, and analyzed for efficacy and safety.
  • Funding: Ziarco Pharma Ltd.

Limitations

  • Small patient sample size.
  • Short study time.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit